Getting to Know Pfizer’s New Chief Medical Officer Aida Habtezion

Our People
aida_habtezion_v2_790x500_0.png
Aida Mobile Tile

Getting to Know Pfizer’s New Chief Medical Officer Aida Habtezion

Changing careers in the middle of a pandemic is no small endeavor. But when Aida Habtezion, M.D., learned about the opportunity to serve as Pfizer’s new Chief Medical Officer, she couldn’t pass it up.

The Facts About Pfizer and BioNTech’s COVID-19 Vaccine

Our Science
young_woman_getting_vaccinated_380x500.png
young_woman_getting_vaccinated_1000x450.png

The Facts About Pfizer and BioNTech’s COVID-19 Vaccine

The U.S. FDA authorization of the Pfizer-BioNTech COVID-19 vaccine for emergency use is a significant step forward in our fight against this pandemic.

COVID-19 SCIENTIFIC RESOURCES

Our Science
COVID-19 SCIENTIFIC RESOURCES
COVID-19 SCIENTIFIC RESOURCES

COVID-19 SCIENTIFIC RESOURCES

Current information on our scientific progress to bring forward a safe and effective vaccine to help protect against the novel coronavirus.

Global Survey Results: Cancer & Aging

News
World_Cancer_Day_790X500_0.jpg
World_Cancer_Day_1000X450_0.jpg

Global Survey Results: Cancer & Aging

This World Cancer Day, we surveyed older people living with cancer and their caregivers.

Find a Trial

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

THE ANTIGEN: #COVID19 PODCAST

Podcasts
the_antigen_image_380x700.png
the_antigen_image_1000x450.jpg

THE ANTIGEN: #COVID19 PODCAST

Season 2 of The Antigen podcast focuses on COVID-19, Pfizer’s response to the crisis and more.

VISIT OUR COVID-19 HUB

Our Science
GettyImages-1208505315_790x500.png
GettyImages-1208505315_1000x450_0_0.jpg

VISIT OUR COVID-19 HUB

Sharing resources to stay safe and updates on our efforts we hope could bring an end to the global health crisis.

Latest News

Approval is based on CROWN trial, which showed a 72% reduction in risk of progression or death for treatment with LORBRENA vs. XALKORI® The U.S. Food and Drug Administration (FDA) approved Pfizer Inc.’s (NYSE: PFE) supplemental New Drug Application (sNDA) for LORBRENA ® (lorlatinib), expanding the indication to include first-line treatment of people with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). LORBRENA is now indicated for adults with metastatic NSCLC whose…